Volumetric changes after 90Y radioembolization for hepatocellular carcinoma in cirrhosis: An option to portal vein embolization in a preoperative setting?

Annals of Surgical Oncology

Volumn 20, Issue 8, 2013, Pages 2518-2525

  Edeline, Julien ^a,b,c   Lenoir, Laurence ^a,b,c   Boudjema, Karim ^c,d   Rolland, Yan ^a,b   Boulic, Anne ^d   Le Du, Fanny ^a   Pracht, Marc ^a,b   Raoul, Jean Luc ^e   Clément, Bruno ^b   Garin, Etienne ^a,b,c   Boucher, Eveline ^a  

^a Eugène Marquis   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER WEIGHT; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PREOPERATIVE TREATMENT; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SURVIVAL TIME;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; HYPERTROPHY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY; ORGAN SIZE; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84880273163     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2906-9     Document Type: Article

References (33)

1. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol. 2010;7:41-9.
2. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56:464-73.
3. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587-96.
4. Gulec SA, Pennington K, Hall M, et al. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
5. Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-6.
6. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43.
7. Bartoli M, Boisson RC, Chevenne F, et al. Non invasive assessment of liver fibrosis: guidelines of the French National Authority for health and comments of the working group "Biological Markers of Liver Fibrosis" of the French Society of Clinical Biology. Ann Biol Clin (Paris). 2007;65:449-52.
8. Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265-78.
9. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
11. 90yttrium microspheres. Dig Dis Sci. 2008;53:2556-63.
12. ®): assessment of hepatic arterial embolization. Cardiovasc Interv Radiol. 2006;29:522-9.
13. Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol. 2010;102:960-7.
14. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232:665.
15. Denys A, Lacombe C, Schneider F, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol. 2005;16:1667-74.
16. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208.
17. Giraudo G, Greget M, Oussoultzoglou E, et al. Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. Surgery. 2008;143:476-82.
18. Lee KC, Kinoshita H, Hirohashi K, Kubo S, Iwasa R. Extension of surgical indications for hepatocellular carcinoma by portal vein embolization. World J Surg. 1993;17:109-15.
19. Liu H, Zhu S. Present status and future perspectives of preoperative portal vein embolization. Am J Surg. 2009;197:686-90.
20. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005;16:779-90.
21. Madoff DC, Hicks ME, Vauthey JN, et al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics. 2002;22:1063-76.
22. Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery. 2009;145:399-405.
23. Ji W, Liu WH, Ma KS, et al. Preoperative selective portal vein embolization in two-step hepatectomy for hepatocellular carcinoma in injured livers: a preliminary report. HBPD Int. 2003;2:216-20.
24. Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:1091-8.
25. Whitney R, Tatum C, Hahl M, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2011;166:236-40.
26. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2.
27. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-8.
28. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma. Cancer. 2010;116:1305-14.
29. Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139:766.
30. Iñarrairaegui M, Pardo F, Bilbao JI, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2012;38:594-601.
31. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062.
32. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol. 2011;55:1309-16.
33. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with Sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147-56.